Mortality risk among sulfonylureas: A systematic review and network meta-analysis

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 1, 2015, Pages 43-51

  Simpson, Scot H ^a   Lee, Jayson ^a   Choi, Sabina ^a   Vandermeer, Ben ^b   Abdelmoneim, Ahmed S ^a   Featherstone, Travis R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; ANTIDIABETIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DRUG FATALITY; EMBASE; HEART INFARCTION; HUMAN; MEDICAL DECISION MAKING; MEDLINE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; AGED; CAUSE OF DEATH; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; MIDDLE AGED; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; FEMALE; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84927563050     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70213-X     Document Type: Article

References (74)

1. Harper W, Clement M, Goldenberg R, et al. Pharmacologic management of type 2 diabetes. Can J Diabetes 2013, 37(suppl 1):S61-S68.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study Group.
4. Bell DS Do sulfonylurea drugs increase the risk of cardiac events?. Can Med Assoc J 2006, 174:185-186.
5. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999, 33:119-124.
6. Johnson JA, Majumdar SR, Simpson SH, Toth EL Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002, 25:2244-2248.
7. Evans JM, Ogston SA, Emslie-Smith A, Morris AD Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006, 49:930-936.
8. Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010, 33:1224-1229.
9. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012, 380:475-483.
10. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008, 31:1672-1678.
11. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008, 168:2070-2080.
12. Forst T, Hanefeld M, Jacob S, et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res 2013, 10:302-314.
13. Hemmingsen B, Schroll J, Lund S, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2013, 4. CD009008.
14. Monami M, Genovese S, Mannucci E Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013, 15:938-953.
15. Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 2013, 30:1160-1171.
16. Ashcroft FM, Gribble FM Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complications 2000, 14:192-196.
17. Bolli R Preconditioning: a paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol 2007, 292:H19-H27.
18. Hausenloy DJ, Yellon DM Preconditioning and postconditioning: new strategies for cardioprotection. Diabetes Obes Metab 2008, 10:451-459.
19. Thisted H, Johnsen SP, Rungby J Sulfonylureas and the risk of myocardial infarction. Metabolism 2006, 55(5 suppl 1):S16-S19.
20. Gross GJ, Auchampach JA Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992, 70:223-233.
21. Kristiansen SB, Lofgren B, Nielsen JM, et al. Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes. Diabetologia 2011, 54:451-458.
22. Abdelmoneim AS, Hasenbank SE, Seubert JM, Brocks DR, Light PE, Simpson SH Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab 2012, 14:130-138.
23. Landstedt-Hallin L, Englund A, Adamson U, Lins PE Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 1999, 246:299-307.
24. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003, 26:1485-1489.
25. Nordin C The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia. Acta Diabetol 2014, 51:5-14.
26. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004, 34:535-542.
27. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007, 30:389-394.
28. Hermann LS, Ranstam J, Vaaler S, Melander A Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes. Diabetes Obes Metab 1999, 1:227-232.
29. Gallwitz B, Haupt A, Kraus P, et al. Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al. Diabetes Obes Metab 2010, 12:1127-1128.
30. Abdelmoneim AS, Eurich DT, Gamble JM, Simpson SH Use patterns of antidiabetic regimens by patients with type 2 diabetes. Can J Diabetes 2013, 37:394-400.
31. Leiter LA, Berard L, Bowering CK, et al. Type 2 diabetes mellitus management in Canada: is it improving?. Can J Diabetes 2013, 37:82-89.
32. Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf 2009, 18:973-976.
33. Alexander GC, Sehgal NL, Moloney RM, Stafford RS National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008, 168:2088-2094.
34. Katz HM, Bissel G Blood sugar lowering effects of chlorpropamide and tolbutamide. A double blind cooperative study. Diabetes 1965, 14:650-657.
35. Tan MH, Graham CA, Bradley RF, Gleason RE, Soeldner JS The effects of long-term therapy with oral hypoglycemic agents on the oral glucose tolerance test dynamics in male chemical diabetics. Diabetes 1977, 26:561-570.
36. Baba S, Nakagawa S, Takebe K, et al. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes. Tohoku J Exp Med 1983, 141(suppl):693-706.
37. Kilo C, Meenan A, Bloomgarden Z Glyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus. Clin Ther 1992, 14:801-812.
38. Jennings PE, Scott NA, Saniabadi AR, Belch JJ Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment. Metabolism 1992, 41(5 suppl 1):36-39.
39. Draeger KE, Wernicke-Panten K, Lomp HJ, Schuler E, Rosskamp R Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996, 28:419-425.
40. Potts M, Prata N, Walsh J, Grossman A Parachute approach to evidence based medicine. Br Med J 2006, 333:701-703.
41. Salanti G Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012, 3:80-97.
42. Lumley T Network meta-analysis for indirect treatment comparisons. Stat Med 2002, 21:2313-2324.
43. Lu G, Ades AE Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23:3105-3124.
44. Abdelmoneim AS, Eurich DT, Gamble JM, et al. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study. Diabetes Obes Metab 2014, 16:22-29.
45. Cochrane handbook for systematic reviews of interventions version 5.1.0 2011, The Cochrane Collaboration, (accessed Aug 1, 2014). http://www.cochrane-handbook.org, J.P. Higgins, S. Green (Eds.).
46. Moher D, Liberati A, Tetzlaff J, Altman DG Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA statement. PLoS Medicine 2009, 6:e1000097.
47. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
48. Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011, 14:429-437.
49. Downs SH, Black N The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998, 52:377-384.
50. Pantalone KM, Kattan MW, Yu C, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 2012, 14:803-809.
51. Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis. Diabet Med 2012, 29:1029-1035.
52. Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007, 23:479-484.
53. Monami M, Luzzi C, Lamanna C, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006, 22:477-482.
54. Mannucci E, Monami M, Masotti G, Marchionni N All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 2004, 20:44-47.
55. Johnsen SP, Monster TB, Olsen ML, et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 2006, 13:134-140.
56. Horsdal HT, Johnsen SP, Sondergaard F, et al. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev 2009, 25:515-522.
57. Jorgensen CH, Gislason GH, Bretler D, et al. Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction-a nationwide study. Int J Cardiol 2011, 152:327-331.
58. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011, 32:1900-1908.
59. DerSimonian R, Laird N Meta-analysis in clinical trials. Cont Clin Trials 1986, 7:177-188.
60. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G Evaluation of inconsistency in networks of interventions. Int J Epidemiol 2013, 42:332-345.
61. Bo S, Castiglione A, Ghigo E, et al. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. Eur J Endocrinol 2013, 169:117-126.
62. Juurlink DN, Gomes T, Shah BR, Mamdani MM Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. Diabet Med 2012, 29:1524-1528.
63. Sillars B, Davis WA, Hirsch IB, Davis TM Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab 2010, 12:757-765.
64. Khalangot M, Tronko M, Kravchenko V, Kovtun V Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 2009, 86:247-253.
65. Arruda-Olson AM, Patch RK, Leibson CL, et al. Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clin Proc 2009, 84:28-33.
66. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. for the ACCORD Study Group.
67. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008, 29:166-176. for the DIGAMI 2 Investigators.
68. Pogatsa G, Koltai MZ, Jermendy G, Simon J, Aranyi Z, Ballagi-Pordany G The effect of sulphonylurea therapy on the outcome of coronary heart diseases in diabetic patients. Acta Med Hung 1992, 49:39-51.
69. Horsdal HT, Sondergaard F, Johnsen SP, Rungby J Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study. Pharmacoepidemiol Drug Safety 2011, 20:331-337.
70. Vaccaro O, Masulli M, Bonora E, et al. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Nutr Metab Cardiovasc Dis 2012, 22:997-1006.
71. Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013, 10:289-301.
72. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. for the ADVANCE Collaborative Group.
73. Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009, 120:2529-2540. for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group.
74. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135. for the RECORD Study Team.